Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2550 of 2873 entries
View as:

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

Phase: N/A Priority: Normal
NCT ID: NCT01200004 Org: User:
Start: 04/30/12 End: 07/31/13 Due: 07/31/14

Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT02131597 Org: User:
Start: 11/10/14 End: 07/25/24 Due: 07/25/25

Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems

Phase: N/A Priority: Normal
NCT ID: NCT01193036 Org: User:
Start: 08/31/10 End: 12/31/13 Due: 12/31/14

Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02478320 Org: User:
Start: 08/05/16 End: 05/12/22 Due: 05/12/23

A Pilot Study to Evaluate Nipple-Areolar Complex (NAC) Sparing Mastectomy

Phase: N/A Priority: Normal
NCT ID: NCT00539227 Org: User:
Start: 10/31/07 End: 07/31/13 Due: 07/31/14

Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03422302 Org: User:
Start: 03/16/18 End: 05/31/28 Due: 05/31/29

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06200155 Org: User:
Start: 04/16/24 End: 12/31/26 Due: 12/31/27

Hepatic Artery Infusion of CD34+ Cells

Phase: N/A Priority: Normal
NCT ID: NCT00062543 Org: User:
Start: 05/31/02 End: 10/31/05 Due: 10/31/06

Treatment of Resectable Malignant Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00415467 Org: User:
Start: 01/31/05 End: 07/31/08 Due: 07/31/09

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Phase: N/A Priority: Normal
NCT ID: NCT06004336 Org: User:
Start: 10/31/23 End: 01/01/29 Due: 01/01/30

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00826449 Org: User:
Start: 02/28/09 End: 06/30/14 Due: 06/30/15

Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study

Phase: N/A Priority: Normal
NCT ID: NCT02302859 Org: User:
Start: 01/31/15 End: 03/31/16 Due: 03/31/17

Compassionate Access of the Miltenyi Device for CD34+ Cell Selection

Phase: N/A Priority: Normal
NCT ID: NCT02438904 Org: User:
Start: 05/06/15 End: 05/01/27 Due: 05/01/28

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02366130 Org: User:
Start: 02/11/15 End: 12/16/20 Due: 12/16/21

PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening

Phase: N/A Priority: Normal
NCT ID: NCT02286713 Org: User:
Start: 03/31/15 End: 12/30/20 Due: 12/30/21

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Phase: N/A Priority: Normal
NCT ID: NCT05026983 Org: User:
Start: 12/27/21 End: 05/01/25 Due: 05/01/26

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Phase: N/A Priority: Normal
NCT ID: NCT05040568 Org: User:
Start: 02/28/22 End: 02/02/27 Due: 02/02/28

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01548144 Org: User:
Start: 04/30/12 End: 08/26/21 Due: 08/26/22

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01729091 Org: User:
Start: 06/10/13 End: 06/25/24 Due: 06/25/25

Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00038181 Org: User:
Start: 10/05/00 End: 11/29/05 Due: 11/29/06

Children's Resiliency, Adjustment, and Coping

Phase: N/A Priority: Normal
NCT ID: NCT00489632 Org: User:
Start: 04/30/06 End: 01/31/11 Due: 01/31/12

Increasing Access to Smoking Cessation and Smoke Free Home Services for Low-Income Pregnant Women in Northeast Texas

Phase: N/A Priority: Normal
NCT ID: NCT05051345 Org: User:
Start: 02/18/20 End: 02/02/27 Due: 02/02/28

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04388852 Org: User:
Start: 08/20/20 End: 12/31/26 Due: 12/31/27

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Phase: N/A Priority: Normal
NCT ID: NCT00329043 Org: User:
Start: 05/15/06 End: 12/31/25 Due: 12/31/26

Phase II Evaluation of Exhaled Nitric Oxide (NO)

Phase: N/A Priority: Normal
NCT ID: NCT01392144 Org: User:
Start: 08/31/11 End: 02/28/13 Due: 02/28/14